Phibro Animal Health (NASDAQ:PAHC) PT Set at $26.00 by Morgan Stanley

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) has been given a $26.00 price objective by equities research analysts at Morgan Stanley in a report released on Wednesday, Marketbeat.com reports. The brokerage currently has an "equal weight" rating on the stock. Morgan Stanley's target price would indicate a potential upside of 1.33% from the stock's previous close.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a research report on Monday, June 16th. Finally, BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a research report on Monday, June 16th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $21.80.

Phibro Animal Health Stock Performance

PAHC stock traded up $0.54 during mid-day trading on Wednesday, reaching $25.66. 741,649 shares of the stock traded hands, compared to its average volume of 211,804. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $26.55. The business has a 50-day moving average of $22.62 and a two-hundred day moving average of $21.97. The firm has a market capitalization of $1.04 billion, a PE ratio of 32.90, a P/E/G ratio of 0.47 and a beta of 0.74.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.11. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. The business had revenue of $347.80 million during the quarter, compared to analysts' expectations of $352.41 million. As a group, equities analysts predict that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Institutional Trading of Phibro Animal Health

Hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Phibro Animal Health during the fourth quarter worth approximately $29,000. National Bank of Canada FI acquired a new stake in shares of Phibro Animal Health during the first quarter worth approximately $30,000. Lazard Asset Management LLC increased its holdings in shares of Phibro Animal Health by 2,739.7% during the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after buying an additional 1,589 shares in the last quarter. Virtus Fund Advisers LLC acquired a new stake in shares of Phibro Animal Health during the fourth quarter worth approximately $69,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Phibro Animal Health during the fourth quarter worth approximately $69,000. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.